The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit.
Melanoma is a highly metastatic cancer, and there are no current therapeutic modalities to treat this deadly malignant disease once it has metastasized. Melanoma cancers exhibit B-RAF mutations in up to 70% of cases. B-RAF mutations are responsible, in large part, for the constitutive hyperactivation of survival/antiapoptotic pathways such as the MAPK, NF-κB, and PI3K/AKT. These hyperactivated pathways regulate the expression of genes targeting the initiation of the metastatic cascade, namely, the epithelial to mesenchymal transition (EMT). EMT is the result of the expression of mesenchymal gene products such as fibronectin, vimentin, and metalloproteinases and the invasion and inhibition of E-cadherin. The above pathways cross-talk and regulate each other's activities and functions. For instance, the NF-κB pathway directly regulates EMT through the transcription of gene products involved in EMT and indirectly through the transcriptional up-regulation of the metastasis inducer Snail. Snail, in turn, suppresses the expression of the metastasis suppressor gene product Raf kinase inhibitor protein RKIP (inhibits the MAPK and the NF-κB pathways) as well as PTEN (inhibits the PI3K/AKT pathway). The role of B-RAF mutations in melanoma and their direct role in the induction of EMT are not clear. This review discusses the hypothesis that B-RAF mutations are involved in the dysregulation of the NF-κB/Snail/RKIP/PTEN circuit and in both the induction of EMT and metastasis. The therapeutic implications of the dysregulation of the above circuit by B-RAF mutations are such that they offer novel targets for therapeutic interventions in the treatment of EMT and metastasis.
Lin
Kimberly
K
Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA.
Baritaki
Stavroula
S
Militello
Loredana
L
Malaponte
Graziella
G
Bevelacqua
Ylenia
Y
Bonavida
Benjamin
B
Br J Cancer. 2006 Sep 4;95(5):581-6
16880785
Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85
15520807
J Transl Med. 2009 Oct 14;7:86
19828018
J Biol Chem. 1998 May 29;273(22):13375-8
9593664
Nature. 2006 Jan 19;439(7074):358-62
16273091
Onkologie. 2008 Jul;31(7):398-403
18596389
Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4
10685652
EMBO J. 2001 Jul 16;20(14):3716-27
11447113
Curr Biol. 2005 Feb 8;15(3):249-54
15694309
Curr Opin Pharmacol. 2008 Aug;8(4):419-26
18644254
Cancer Res. 2003 Jul 15;63(14):3883-5
12873977
Oncogene. 2008 Apr 3;27(15):2243-8
17952120
J Biol Chem. 2004 Jul 23;279(30):31769-79
15145934
Cancer Invest. 2008 Jun;26(5):516-34
18568775
J Clin Invest. 2004 Aug;114(4):569-81
15314694
Biochim Biophys Acta. 2009 Dec;1796(2):293-308
19683560
J Invest Dermatol. 2008 Nov;128(11):2575-2595
18927540
Oncogene. 2007 Mar 22;26(13):1954-8
17001349
Mol Cell Biol. 2001 Nov;21(21):7207-17
11585904
Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix
19464601
Mol Cell Biol. 2008 Mar;28(5):1528-40
18172008
FEBS Lett. 2008 Jun 11;582(13):1821-8
18472007
Mol Cancer Res. 2006 Nov;4(11):803-10
17077165
J Cutan Pathol. 2007 Mar;34(3):220-5
17302605
Cancer Res. 2001 Jun 15;61(12):4901-9
11406569
Endocr Rev. 2001 Apr;22(2):153-83
11294822
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s
16609060
J Biol Chem. 2001 Jul 6;276(27):24661-6
11323412
Science. 1997 Mar 28;275(5308):1943-7
9072974
J Cell Biol. 1995 Nov;131(3):791-805
7593197
J Clin Oncol. 1996 Jan;14(1):7-17
8558223
Biochim Biophys Acta. 2007 Aug;1773(8):1299-310
17188374
Biochem J. 2004 Aug 15;382(Pt 1):1-11
15193142
Curr Opin Genet Dev. 1998 Feb;8(1):49-54
9529605
Nat Genet. 2003 Jan;33(1):19-20
12447372
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cell. 1989 Jul 28;58(2):227-9
2665943
J Biol Chem. 1995 Jan 6;270(1):269-73
7814385
Pigment Cell Melanoma Res. 2009 Aug;22(4):400-19
19493313
Cancer Cell. 2004 Oct;6(4):313-9
15488754
Methods Enzymol. 2008;439:25-38
18374154
Cancer Res. 2009 Nov 1;69(21):8376-85
19843864
J Biol Chem. 1994 Oct 28;269(43):26602-5
7929388
Cancer Metastasis Rev. 2005 Jun;24(2):273-85
15986137
J Cell Sci. 2003 May 15;116(Pt 10):1959-67
12668723
Anticancer Res. 2001 Nov-Dec;21(6B):4207-19
11908674
J Am Acad Dermatol. 1998 May;38(5 Pt 1):716-30
9591817
Nat Genet. 1998 Aug;19(4):348-55
9697695
J Biol Chem. 2004 Apr 23;279(17):17515-23
14766752
Oncogene. 2004 Sep 23;23(44):7345-54
15286702
Clin Cancer Res. 2002 Dec;8(12):3728-33
12473582
Nature. 2002 Jun 27;417(6892):949-54
12068308
J Exp Med. 2009 Jan 16;206(1):221-32
19124656
J Cell Sci. 2004 Apr 1;117(Pt 9):1675-85
15075229
J Biol Chem. 2001 Jun 1;276(22):18934-40
11259436
Nat Cell Biol. 2000 Feb;2(2):76-83
10655586
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3537-42
9520401
Cancer Cell. 2002 Oct;2(4):275-8
12398891
Oncogene. 2005 May 12;24(21):3535-40
15782137
N Engl J Med. 2006 Jul 6;355(1):51-65
16822996
Cancer Cell. 2005 Dec;8(6):443-54
16338658
Mol Biol Cell. 1995 Jul;6(7):841-50
7579698
Int J Oncol. 2009 Jun;34(6):1481-9
19424565
Science. 1994 Sep 2;265(5177):1458-61
8073291
J Natl Cancer Inst. 1999 Nov 3;91(21):1820-8
10547389
Cell. 2004 Mar 19;116(6):855-67
15035987
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9
19661225
Cancer Res. 2005 Nov 15;65(22):10164-9
16288000
J Invest Dermatol. 2008 Aug;128(8):2003-12
18323787
Curr Oncol Rep. 2010 May;12(3):146-52
20425073
J Biol Chem. 2003 Sep 5;278(36):34548-54
12821662
J Biol Chem. 1993 Oct 5;268(28):20701-4
8407889
Cancer Biol Ther. 2006 Sep;5(9):1065-73
16969122
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1047-57
19029025
J Natl Cancer Inst. 2003 Jun 18;95(12):878-89
12813171
J Clin Oncol. 2001 Aug 15;19(16):3635-48
11504745
Front Biosci (Landmark Ed). 2009 Jan 01;14:918-28
19273108
J Biol Chem. 2002 Mar 8;277(10):7920-8
11773061
EMBO J. 2000 Oct 16;19(20):5429-39
11032810
Adv Exp Med Biol. 2008;624:104-16
18348451
Pigment Cell Melanoma Res. 2010 Feb;23(1):41-56
19843243
Cancer Res. 2006 Aug 15;66(16):7833-6
16912153
Oncogene. 1998 Jul 2;16(26):3397-402
9692547
Adv Cancer Res. 2009;102:19-65
19595306
Arch Surg. 1991 Apr;126(4):438-41
2009058
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10148-52
7937853
Cell Signal. 2008 Jan;20(1):1-9
17706925
Nat Genet. 1997 Apr;15(4):356-62
9090379
Cancer Res. 2004 May 15;64(10):3428-35
15150094
Int J Oncol. 2003 Apr;22(4):891-8
12632084
J Natl Cancer Inst. 2010 Feb 24;102(4):214-5
20145213
J Cell Sci. 2002 Jan 1;115(Pt 1):141-51
11801732
Cancer Metastasis Rev. 2005 Jun;24(2):301-13
15986139
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50
9560261
Br J Cancer. 2004 Mar 22;90(6):1265-73
15026811
Cancer Res. 2002 Dec 1;62(23):6997-7000
12460918
Genes Dev. 1999 Nov 15;13(22):2905-27
10579998
Cancer Res. 2008 May 1;68(9):3429-39
18451171
Nature. 1999 Sep 9;401(6749):173-7
10490027
Nat Genet. 2009 May;41(5):544-52
19282848
Cancer Res. 2003 Dec 1;63(23):8132-7
14678966